Candel Therapeutics (CADL) Gains from Investment Securities: 2020-2024
Historic Gains from Investment Securities for Candel Therapeutics (CADL) over the last 5 years, with Dec 2024 value amounting to $20.8 million.
- Candel Therapeutics' Gains from Investment Securities rose 117.60% to $483,000 in Q4 2023 from the same period last year, while for Dec 2023 it was -$8.0 million, marking a year-over-year increase of 68.43%. This contributed to the annual value of $20.8 million for FY2024, which is 2253.42% up from last year.
- As of FY2024, Candel Therapeutics' Gains from Investment Securities stood at $20.8 million, which was up 2,253.42% from -$966,000 recorded in FY2023.
- In the past 5 years, Candel Therapeutics' Gains from Investment Securities ranged from a high of $20.8 million in FY2024 and a low of -$966,000 during FY2023.
- Its 3-year average for Gains from Investment Securities is $8.5 million, with a median of $5.6 million in 2022.
- As far as peak fluctuations go, Candel Therapeutics' Gains from Investment Securities plummeted by 117.11% in 2023, and later spiked by 2,253.42% in 2024.
- Yearly analysis of 5 years shows Candel Therapeutics' Gains from Investment Securities stood at $4.0 million in 2020, then rose by 19.19% to $4.8 million in 2021, then grew by 18.02% to $5.6 million in 2022, then tumbled by 117.11% to -$966,000 in 2023, then surged by 2,253.42% to $20.8 million in 2024.